The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I study. The molecule exhibits potent in vitro and in…
Home > BMS-986318
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.